

## Transaction Contacts

Coverage Team:  
Dan Dubin, M.D.  
Sean Pitt

ECM Team:  
Rahul Chaudhary

**aura**

**\$99 Million**

Follow-On Offering

**LEERINK**   
PARTNERS

Lead-Left Bookrunner

November 2023

# Leerink Partners Serves as Lead-Left Bookrunner for Aura Biosciences' (Nasdaq: AURA) \$99 Million Follow-on Offering

## Key Transaction Highlights

- Confidentially marketed deal that publicly launched on November 6th (post-close) and priced overnight
- Base deal consisted of 11,000,000 shares of common stock at a price of \$9.00 per share, representing an 18% discount to last sale.
- Aura Biosciences intends to use the net proceeds from this offering, together with existing cash, cash equivalents and marketable securities, to advance the clinical development of belzupacap sarotalocan for the treatment of choroidal melanoma and choroidal metastasis, to develop the platform and for general corporate purposes.
- This is Leerink Partners' 3rd bookrun offering for Aura Biosciences and 48th equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF LEERINK PARTNERS LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON  
53 State Street  
40th Floor  
Boston, MA 02109

CHARLOTTE  
2151 Hawkins Street  
Suite 1025  
Charlotte, NC 28203

NASHVILLE  
40 Burton Hills Boulevard  
Suite 200  
Nashville, TN 37215

NEW YORK  
1301 Avenue of the Americas  
12th Floor  
New York, NY 10019

SAN FRANCISCO  
255 California Street  
12th Floor  
San Francisco, CA 94111

[LEERINK.COM](https://www.leerink.com)